| Three Months Ended December 31, 2025 (2024) | Twelve Months Ended December 31, 2025 (2024) | |
| Revenue was SEK 4.6 M (313.4 M) | Revenue was SEK 434.4 M (334.7 M) | |
| Operating profit/loss was SEK -46.5 M (290.4 M) | Operating profit/loss was SEK 271.0 M (241.9 M) | |
| Net profit/loss was SEK -41.7 M (247.1 M) | Net profit/loss was SEK 284.6 M (188.7 M) | |
| Cash and cash equivalent SEK 580.8 M (303.3) | Cash and cash equivalent SEK 580.8 M (303.3) | |
| Basic earnings/loss per share was SEK -0.30 (2.21) | Basic earnings/loss per share was SEK 2.21 (1.77) | |
| Diluted earnings/loss per share were SEK -0.30 (2.17) | Diluted earnings/loss per share were SEK 2.15 (1.76) |
Business highlights in Q4 2025
Comments from the CEO
“Our mission is to leverage our ion channel targeting expertise to discover, develop, and deliver innovative therapies on our own and in collaboration with partners. Our partnerships validate the strength of our science and reinforce our financial foundation. We are entering a phase of disciplined clinical execution, advancing multiple proprietary programs toward the clinic and translating innovation into meaningful value for patients in need and for our shareholders.”
Investor call
Saniona will host a Q4 & year-end investor call on 26 February 2026, at 11.00 CET.
At the call Management will be presenting results and a company update. At the end of the presentation there will be a Q&A session, where participants can ask online questions.
Access to the event can be obtained through the following link:
Live Q&A - Saniona
REPLAY access
Webcast replay will be available at www.saniona.com and at www.redeye.se